Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Apr 18, 2023
Proposed transaction would provide Coeptis with two clinical stage assets leveraging NK cell therapies in relapsed or refractory acute myeloid leukemia (AML) and hospitalized respiratory...
-
Mar 29, 2023
Potential acquisition of VyGen-Bio would strengthen Coeptis' oncology pipeline by obtaining exclusive, worldwide ownership rights to GEAR™ Platform and companion diagnostic technologies WEXFORD, Pa.
-
Mar 21, 2023
SNAP-CAR recognized in research detailing advances in modulating chimeric antigen receptor (CAR) T cell activity for improved safety, efficacy, and flexibility WEXFORD, Pa., March 21, 2023 /PRNewswire
-
Feb 7, 2023
Coeptis strengthens measures to protect shareholder interests through ShareIntel's investigation and due diligence services WEXFORD, Pa., Feb. 7, 2023 /PRNewswire/ -- Coeptis Therapeutics...
-
Jan 31, 2023
Coeptis to collaborate with the University of Pittsburgh to expand pre-clinical development of SNAP-CAR T cells targeting HER2-positive cancers WEXFORD, Pa., Jan. 31, 2023 /PRNewswire/ -- Coeptis...